ES2688084T3 - Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A - Google Patents
Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A Download PDFInfo
- Publication number
- ES2688084T3 ES2688084T3 ES15730261.3T ES15730261T ES2688084T3 ES 2688084 T3 ES2688084 T3 ES 2688084T3 ES 15730261 T ES15730261 T ES 15730261T ES 2688084 T3 ES2688084 T3 ES 2688084T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- formula
- triazolo
- compound
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title description 10
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 title description 9
- 239000003112 inhibitor Substances 0.000 title description 5
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 120
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 4
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 208000028017 Psychotic disease Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000003920 cognitive function Effects 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000016285 Movement disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000007658 neurological function Effects 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000000543 intermediate Substances 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 37
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- -1 carbamoyl-substituted imidazo [1,2-a] pyridine core Chemical group 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 150000004985 diamines Chemical class 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229910052721 tungsten Inorganic materials 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- NUJBTXFFJUGENN-UHFFFAOYSA-N ethyl 3,4-diaminobenzoate Chemical compound CCOC(=O)C1=CC=C(N)C(N)=C1 NUJBTXFFJUGENN-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 3
- DFEJKANZSXPIPE-UHFFFAOYSA-N 2-imino-4,6-dimethylpyrimidin-1-amine Chemical compound CC=1C=C(C)N(N)C(=N)N=1 DFEJKANZSXPIPE-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- BEQVQKJCLJBTKZ-UHFFFAOYSA-M diphenylphosphinate Chemical compound C=1C=CC=CC=1P(=O)([O-])C1=CC=CC=C1 BEQVQKJCLJBTKZ-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- JSEQTZXBMOTJCI-UHFFFAOYSA-N 2-[2-(5-chlorothiophen-2-yl)imidazo[1,2-a]pyrimidin-7-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound ClC1=CC=C(S1)C=1N=C2N(C=CC(=N2)C2=NN3C(C(=NC=C3C)C)=N2)C=1 JSEQTZXBMOTJCI-UHFFFAOYSA-N 0.000 description 2
- HYZYHVUIWRRMEZ-UHFFFAOYSA-N 3,6-dimethylpyrazin-2-amine Chemical compound CC1=CN=C(C)C(N)=N1 HYZYHVUIWRRMEZ-UHFFFAOYSA-N 0.000 description 2
- LAOQNTYYSNQKNC-UHFFFAOYSA-N 4-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,3-oxazole Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=COC=N1 LAOQNTYYSNQKNC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- PGSAVGAWCWMKJF-UHFFFAOYSA-N ethyl 4-amino-5-nitropyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC(N)=C([N+]([O-])=O)C=N1 PGSAVGAWCWMKJF-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000007975 iminium salts Chemical class 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AWKCCJUYQWHDAX-UHFFFAOYSA-N methyl 5-amino-6-nitropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C([N+]([O-])=O)C(N)=C1 AWKCCJUYQWHDAX-UHFFFAOYSA-N 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- ONGOCTRDDWOFAS-UHFFFAOYSA-N 2-(2-benzyl-3H-benzimidazol-5-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound C(C1=CC=CC=C1)C1=NC2=C(N1)C=CC(=C2)C1=NN2C(C(=NC=C2C)C)=N1 ONGOCTRDDWOFAS-UHFFFAOYSA-N 0.000 description 1
- AHKBMBRMFSKZKZ-UHFFFAOYSA-N 2-(6-bromo-2-phenyl-1H-benzimidazol-5-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=C(Br)C=C2NC(=NC2=C1)C1=CC=CC=C1 AHKBMBRMFSKZKZ-UHFFFAOYSA-N 0.000 description 1
- FMKYWWUBBPZFKX-UHFFFAOYSA-N 2-(6-bromo-2-phenylimidazo[1,2-a]pyrimidin-7-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound BrC=1C(=NC=2N(C=1)C=C(N=2)C1=CC=CC=C1)C1=NN2C(C(=NC=C2C)C)=N1 FMKYWWUBBPZFKX-UHFFFAOYSA-N 0.000 description 1
- FTYZGASAWVFMBU-UHFFFAOYSA-N 2-(6-fluoro-2-phenyl-1H-benzimidazol-5-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=C(F)C=C2NC(=NC2=C1)C1=CC=CC=C1 FTYZGASAWVFMBU-UHFFFAOYSA-N 0.000 description 1
- ISUUESMBFUPEGK-UHFFFAOYSA-N 2-(6-fluoro-2-pyridin-2-yl-1H-benzimidazol-5-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=C(F)C=C2NC(=NC2=C1)C1=NC=CC=C1 ISUUESMBFUPEGK-UHFFFAOYSA-N 0.000 description 1
- IDQNBVFPZMCDDN-UHFFFAOYSA-N 2-Amino-4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC(N)=N1 IDQNBVFPZMCDDN-UHFFFAOYSA-N 0.000 description 1
- NTMFMYRBUMKEOU-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound FC1=C(C=CC=C1)C1=NC2=C(N1)C=CC(=C2)C1=NN2C(C(=NC=C2C)C)=N1 NTMFMYRBUMKEOU-UHFFFAOYSA-N 0.000 description 1
- CYZRRJJJSPMKOX-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound COC1=C(C=CC=C1)C1=NC2=CC(=CC=C2N1)C1=NN2C(=N1)C(C)=NC=C2C CYZRRJJJSPMKOX-UHFFFAOYSA-N 0.000 description 1
- BZIDWORUFFLNGU-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)imidazo[1,2-a]pyrimidin-7-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound COC1=C(C=CC=C1)C=1N=C2N(C=CC(=N2)C2=NN3C(C(=NC=C3C)C)=N2)C=1 BZIDWORUFFLNGU-UHFFFAOYSA-N 0.000 description 1
- SBHPGFDMRMCVRX-UHFFFAOYSA-N 2-[2-(3,6-difluoropyridin-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound FC=1C(=NC(=CC=1)F)C1=NC2=C(N1)C=CC(=C2)C1=NN2C(C(=NC=C2C)C)=N1 SBHPGFDMRMCVRX-UHFFFAOYSA-N 0.000 description 1
- YJWRJZCSMZQKDF-UHFFFAOYSA-N 2-[2-(3-bromophenyl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC(Br)=CC=C1 YJWRJZCSMZQKDF-UHFFFAOYSA-N 0.000 description 1
- FUCWNXOPWQVBIU-UHFFFAOYSA-N 2-[2-(3-bromophenyl)imidazo[1,2-a]pyrimidin-7-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound BrC=1C=C(C=CC=1)C=1N=C2N(C=CC(=N2)C2=NN3C(C(=NC=C3C)C)=N2)C=1 FUCWNXOPWQVBIU-UHFFFAOYSA-N 0.000 description 1
- MGXFLBNALZOGMM-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC(F)=CC=C1 MGXFLBNALZOGMM-UHFFFAOYSA-N 0.000 description 1
- POCNJEYXZOYKRH-UHFFFAOYSA-N 2-[2-(3-fluoropyridin-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound FC=1C(=NC=CC=1)C1=NC2=C(N1)C=CC(=C2)C1=NN2C(C(=NC=C2C)C)=N1 POCNJEYXZOYKRH-UHFFFAOYSA-N 0.000 description 1
- BCKNQKOIVLALNV-UHFFFAOYSA-N 2-[2-(3-methoxypyridin-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound COC=1C(=NC=CC=1)C1=NC2=C(N1)C=CC(=C2)C1=NN2C(C(=NC=C2C)C)=N1 BCKNQKOIVLALNV-UHFFFAOYSA-N 0.000 description 1
- ACFLSTWPZCAEMB-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC=C(F)C=C1 ACFLSTWPZCAEMB-UHFFFAOYSA-N 0.000 description 1
- NTTSKWNKVKKFRS-UHFFFAOYSA-N 2-[2-(4-methoxypyridin-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound COC1=CC(=NC=C1)C1=NC2=CC(=CC=C2N1)C1=NN2C(=N1)C(C)=NC=C2C NTTSKWNKVKKFRS-UHFFFAOYSA-N 0.000 description 1
- VUUCDKVXQXXASH-UHFFFAOYSA-N 2-[2-(5-chlorothiophen-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC=C(Cl)S1 VUUCDKVXQXXASH-UHFFFAOYSA-N 0.000 description 1
- VFMDZBCQJFYKDX-UHFFFAOYSA-N 2-[2-(6-fluoropyridin-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=NC(F)=CC=C1 VFMDZBCQJFYKDX-UHFFFAOYSA-N 0.000 description 1
- NINUDVMDTLNUPV-UHFFFAOYSA-N 2-[2-(furan-2-yl)-3H-benzimidazol-5-yl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC=CO1 NINUDVMDTLNUPV-UHFFFAOYSA-N 0.000 description 1
- AUZWRCQJVMSUQF-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,3-benzothiazole Chemical compound S1C(=NC2=C1C=CC=C2)C1=NC2=C(N1)C=CC(=C2)C1=NN2C(C(=NC=C2C)C)=N1 AUZWRCQJVMSUQF-UHFFFAOYSA-N 0.000 description 1
- FOHJIDBAXBCJAJ-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,3-oxazole Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=NC=CO1 FOHJIDBAXBCJAJ-UHFFFAOYSA-N 0.000 description 1
- ANKFMXLEHZORKJ-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,3-thiazole Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C=2SC=CN=2)C=C1)C ANKFMXLEHZORKJ-UHFFFAOYSA-N 0.000 description 1
- VEAXKCMQQYAWGX-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-4-methyl-1,3-thiazole Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C=2SC=C(N=2)C)C=C1)C VEAXKCMQQYAWGX-UHFFFAOYSA-N 0.000 description 1
- XYUBPZIQKORLBE-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-5-methyl-1,3-thiazole Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C=2SC(=CN=2)C)C=C1)C XYUBPZIQKORLBE-UHFFFAOYSA-N 0.000 description 1
- AUTFNKPOAASAPR-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]benzonitrile Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=C(C=CC=C1)C#N AUTFNKPOAASAPR-UHFFFAOYSA-N 0.000 description 1
- NVKFMNHXZHJMRN-UHFFFAOYSA-N 2-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]quinoxaline Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=NC2=CC=CC=C2N=C1 NVKFMNHXZHJMRN-UHFFFAOYSA-N 0.000 description 1
- ZYCQDAAMBJOOGC-UHFFFAOYSA-N 2-[7-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)imidazo[1,2-a]pyrimidin-2-yl]-1,3-thiazole Chemical compound CC1=NC=2N(C(=C1)C)N=C(N=2)C1=NC=2N(C=C1)C=C(N=2)C=1SC=CN=1 ZYCQDAAMBJOOGC-UHFFFAOYSA-N 0.000 description 1
- MRYFITSVZIKRKK-UHFFFAOYSA-N 2-[7-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)imidazo[1,2-a]pyrimidin-2-yl]-1,3-thiazole Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=NC2=NC(=CN2C=C1)C1=NC=CS1 MRYFITSVZIKRKK-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- SDDSSZSKEQLSGW-UHFFFAOYSA-N 2-phenyl-3h-benzimidazole-5-carboxylic acid Chemical compound N1C2=CC(C(=O)O)=CC=C2N=C1C1=CC=CC=C1 SDDSSZSKEQLSGW-UHFFFAOYSA-N 0.000 description 1
- OZFFSBKJCAYWII-UHFFFAOYSA-N 3-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-5-methyl-1,2-oxazole Chemical compound CC1=CC(=NO1)C1=NC2=CC(=CC=C2N1)C1=NN2C(=N1)C(C)=NC=C2C OZFFSBKJCAYWII-UHFFFAOYSA-N 0.000 description 1
- NNBALVIZMGWZHS-UHFFFAOYSA-N 3-chloro-2,5-dimethylpyrazine Chemical compound CC1=CN=C(C)C(Cl)=N1 NNBALVIZMGWZHS-UHFFFAOYSA-N 0.000 description 1
- GVKGLNSEQPNAAG-UHFFFAOYSA-N 4,6-dimethylpyrimidin-1-ium-1,2-diamine diphenylphosphinate Chemical compound Cc1cc(C)[n+](N)c(N)n1.[O-]P(=O)(c1ccccc1)c1ccccc1 GVKGLNSEQPNAAG-UHFFFAOYSA-N 0.000 description 1
- QYQYHMKXZLEGJG-UHFFFAOYSA-N 4-[4-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]phenyl]morpholine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C2=CC=C(C=C2)N2CCOCC2)C=C1)C QYQYHMKXZLEGJG-UHFFFAOYSA-N 0.000 description 1
- BYPZVSQULFQSTK-UHFFFAOYSA-N 4-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,3-thiazole Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C=2N=CSC=2)C=C1)C BYPZVSQULFQSTK-UHFFFAOYSA-N 0.000 description 1
- KJSOIEBVVBWHFR-UHFFFAOYSA-N 4-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-2-phenyl-1H-benzimidazol-5-yl]morpholine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=C(C=C2NC(=NC2=C1)C1=CC=CC=C1)N1CCOCC1 KJSOIEBVVBWHFR-UHFFFAOYSA-N 0.000 description 1
- JRZBTJVSAANBEV-UHFFFAOYSA-N 4-aminopyridine-2-carboxylic acid Chemical compound NC1=CC=NC(C(O)=O)=C1 JRZBTJVSAANBEV-UHFFFAOYSA-N 0.000 description 1
- XHTRHEMAXFRQDD-UHFFFAOYSA-N 4-methyl-N-(4-methylbenzoyl)iminobenzamide Chemical compound C1=CC(C)=CC=C1C(=O)N=NC(=O)C1=CC=C(C)C=C1 XHTRHEMAXFRQDD-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- NSOAUOXMJLJLSM-UHFFFAOYSA-N 5,7-dimethyl-2-(1-methyl-2-pyridin-2-ylbenzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound CC1=NC=2N(C(=C1)C)N=C(N=2)C1=CC2=C(N(C(=N2)C2=NC=CC=C2)C)C=C1 NSOAUOXMJLJLSM-UHFFFAOYSA-N 0.000 description 1
- NGJSCTGVOICSBG-UHFFFAOYSA-N 5,7-dimethyl-2-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound CC1=NC=2N(C(=C1)C)N=C(N=2)C1=NC=2N(C=C1)C=C(N=2)C1=CC=CC=C1 NGJSCTGVOICSBG-UHFFFAOYSA-N 0.000 description 1
- ASIKOYRGPCQQHI-UHFFFAOYSA-N 5,7-dimethyl-2-(2-pyridin-2-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound CC1=NC=2N(C(=C1)C)N=C(N=2)C1=CC2=C(NC(=N2)C2=NC=CC=C2)C=C1 ASIKOYRGPCQQHI-UHFFFAOYSA-N 0.000 description 1
- JCMHHZRQRKXDFQ-UHFFFAOYSA-N 5,7-dimethyl-2-(2-pyridin-2-ylimidazo[1,2-a]pyrimidin-7-yl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound CC1=NC2=NC(=NN2C(C)=C1)C1=NC2=NC(=CN2C=C1)C1=NC=CC=C1 JCMHHZRQRKXDFQ-UHFFFAOYSA-N 0.000 description 1
- MQOWBTLQOGRBSK-UHFFFAOYSA-N 5,7-dimethyl-2-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound CC1=NC2=NC(=NN2C(C)=C1)C1=CC=C2NC(=NC2=C1)C1=CC=NC=C1 MQOWBTLQOGRBSK-UHFFFAOYSA-N 0.000 description 1
- JUYXIJWVPRTAAL-UHFFFAOYSA-N 5,7-dimethyl-2-(3-methyl-2-pyridin-2-ylbenzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound CC1=NC=2N(C(=C1)C)N=C(N=2)C=1C=CC2=C(N(C(=N2)C2=NC=CC=C2)C)C=1 JUYXIJWVPRTAAL-UHFFFAOYSA-N 0.000 description 1
- WXVQCFALDUVKSC-UHFFFAOYSA-N 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine Chemical group N1=C(C)C=C(C)N2N=CN=C21 WXVQCFALDUVKSC-UHFFFAOYSA-N 0.000 description 1
- KGJWQBMMPJWTTD-UHFFFAOYSA-N 5,8-dimethyl-2-(2-phenyl-1H-benzimidazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound Cc1cnc(C)c2nc(nn12)-c1cccc2[nH]c(nc12)-c1ccccc1 KGJWQBMMPJWTTD-UHFFFAOYSA-N 0.000 description 1
- ZOZHIFOCCJPYGJ-UHFFFAOYSA-N 5,8-dimethyl-2-(2-phenyl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC=CC=C1 ZOZHIFOCCJPYGJ-UHFFFAOYSA-N 0.000 description 1
- CJVXFXNWLNLYQU-UHFFFAOYSA-N 5,8-dimethyl-2-(2-phenyl-3H-imidazo[4,5-c]pyridin-6-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC2=C(NC(=N2)C2=CC=CC=C2)C=N1 CJVXFXNWLNLYQU-UHFFFAOYSA-N 0.000 description 1
- MSWGVRZPKBAHQI-UHFFFAOYSA-N 5,8-dimethyl-2-(2-phenyl-6-pyrrolidin-1-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C2=CC=CC=C2)C=C1N1CCCC1)C MSWGVRZPKBAHQI-UHFFFAOYSA-N 0.000 description 1
- ROQYSSJKWZQFRS-UHFFFAOYSA-N 5,8-dimethyl-2-(2-phenyl-6-pyrrolidin-1-ylimidazo[1,2-a]pyrimidin-7-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=NC=2N(C=C1N1CCCC1)C=C(N=2)C1=CC=CC=C1)C ROQYSSJKWZQFRS-UHFFFAOYSA-N 0.000 description 1
- NOMUTGPBGBALKA-UHFFFAOYSA-N 5,8-dimethyl-2-(2-pyridazin-3-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC=CN=N1 NOMUTGPBGBALKA-UHFFFAOYSA-N 0.000 description 1
- CQPLWGHMXBOGJC-UHFFFAOYSA-N 5,8-dimethyl-2-(2-pyridin-2-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=NC=CC=C1 CQPLWGHMXBOGJC-UHFFFAOYSA-N 0.000 description 1
- ZFDPGPPINLDECS-UHFFFAOYSA-N 5,8-dimethyl-2-(2-pyridin-2-ylimidazo[1,2-a]pyrimidin-7-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=NC=2N(C=C1)C=C(N=2)C1=NC=CC=C1)C ZFDPGPPINLDECS-UHFFFAOYSA-N 0.000 description 1
- YCHCKKIRFVDACM-UHFFFAOYSA-N 5,8-dimethyl-2-(2-pyridin-3-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CC=CN=C1 YCHCKKIRFVDACM-UHFFFAOYSA-N 0.000 description 1
- IQLOGUSBOICIPD-UHFFFAOYSA-N 5,8-dimethyl-2-(2-thiophen-2-yl-3H-benzimidazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C=2SC=CC=2)C=C1)C IQLOGUSBOICIPD-UHFFFAOYSA-N 0.000 description 1
- KCQKVXXSRSLXRR-UHFFFAOYSA-N 5,8-dimethyl-2-(2-thiophen-2-ylimidazo[1,2-a]pyrimidin-7-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=NC=2N(C=C1)C=C(N=2)C=1SC=CC=1)C KCQKVXXSRSLXRR-UHFFFAOYSA-N 0.000 description 1
- FWBMOLUPKHZRML-UHFFFAOYSA-N 5,8-dimethyl-2-[2-(1-methylimidazol-2-yl)-3H-benzimidazol-5-yl]-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C=2N(C=CN=2)C)C=C1)C FWBMOLUPKHZRML-UHFFFAOYSA-N 0.000 description 1
- OSPXTLOGZMHKNJ-UHFFFAOYSA-N 5,8-dimethyl-2-[2-(2-methylphenyl)-3H-benzimidazol-5-yl]-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=C(C)C=CC=C1 OSPXTLOGZMHKNJ-UHFFFAOYSA-N 0.000 description 1
- HCOYOGOIVGKEAN-UHFFFAOYSA-N 5,8-dimethyl-2-[2-(3-methylpyrazin-2-yl)-3H-benzimidazol-5-yl]-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=C(C)N=CC=N1 HCOYOGOIVGKEAN-UHFFFAOYSA-N 0.000 description 1
- BFQZYQHFKBFORH-UHFFFAOYSA-N 5,8-dimethyl-2-[2-(3-pyrrolidin-1-ylphenyl)imidazo[1,2-a]pyrimidin-7-yl]-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=NC=2N(C=C1)C=C(N=2)C1=CC(=CC=C1)N1CCCC1)C BFQZYQHFKBFORH-UHFFFAOYSA-N 0.000 description 1
- LZJJATLYUVJUFT-UHFFFAOYSA-N 5,8-dimethyl-2-[6-(4-methylpiperazin-1-yl)-2-phenylimidazo[1,2-a]pyrimidin-7-yl]-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CN1CCN(CC1)C1=CN2C=C(N=C2N=C1C1=NN2C(=N1)C(C)=NC=C2C)C1=CC=CC=C1 LZJJATLYUVJUFT-UHFFFAOYSA-N 0.000 description 1
- OVGBICIMKVMTBR-UHFFFAOYSA-N 5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical group CC1=CN=C(C)C2=NC=NN12 OVGBICIMKVMTBR-UHFFFAOYSA-N 0.000 description 1
- NHIPVZOVZISHGE-UHFFFAOYSA-N 5-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,2-oxazole Chemical compound CC1=CN=C(C=2N1N=C(N=2)C1=CC2=C(NC(=N2)C2=CC=NO2)C=C1)C NHIPVZOVZISHGE-UHFFFAOYSA-N 0.000 description 1
- VVXLORMZKYTCLZ-UHFFFAOYSA-N 5-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-1,3-thiazole Chemical compound CC1=CN=C(C)C2=NC(=NN12)C1=CC=C2NC(=NC2=C1)C1=CN=CS1 VVXLORMZKYTCLZ-UHFFFAOYSA-N 0.000 description 1
- KPAZELHKOHOWJI-UHFFFAOYSA-N 5-[6-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-1H-benzimidazol-2-yl]-3-methyl-1,2-oxazole Chemical compound CC1=NOC(=C1)C1=NC2=CC(=CC=C2N1)C1=NN2C(=N1)C(C)=NC=C2C KPAZELHKOHOWJI-UHFFFAOYSA-N 0.000 description 1
- NOJGXSKFLSJLSC-UHFFFAOYSA-N 5-amino-6-nitropyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1[N+]([O-])=O NOJGXSKFLSJLSC-UHFFFAOYSA-N 0.000 description 1
- BYIORJAACCWFPU-UHFFFAOYSA-N 5-aminonicotinic acid Chemical compound NC1=CN=CC(C(O)=O)=C1 BYIORJAACCWFPU-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- IXUAKHLJLPKQLZ-UHFFFAOYSA-N 6,8-dimethyl-2-(2-phenyl-1H-imidazo[4,5-b]pyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC=1N=C(C=2N(C=1)N=C(N=2)C1=CC=C2C(=N1)NC(=N2)C1=CC=CC=C1)C IXUAKHLJLPKQLZ-UHFFFAOYSA-N 0.000 description 1
- LCJXSRQGDONHRK-UHFFFAOYSA-N 6-methyl-3-nitropyridin-2-amine Chemical compound CC1=CC=C([N+]([O-])=O)C(N)=N1 LCJXSRQGDONHRK-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical class CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010070606 Post stroke depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CRUSIXIPTRGLBE-UHFFFAOYSA-N ethyl 2-(1-methylimidazol-2-yl)-3H-benzimidazole-5-carboxylate Chemical compound CN1C(=NC=C1)C1=NC2=C(N1)C=CC(=C2)C(=O)OCC CRUSIXIPTRGLBE-UHFFFAOYSA-N 0.000 description 1
- YULRTSAHHGQIGD-UHFFFAOYSA-N ethyl 2-(2-fluorophenyl)-3h-benzimidazole-5-carboxylate Chemical compound N1C2=CC(C(=O)OCC)=CC=C2N=C1C1=CC=CC=C1F YULRTSAHHGQIGD-UHFFFAOYSA-N 0.000 description 1
- FITUVUIPBMPKJQ-UHFFFAOYSA-N ethyl 2-benzyl-3h-benzimidazole-5-carboxylate Chemical compound N1C2=CC(C(=O)OCC)=CC=C2N=C1CC1=CC=CC=C1 FITUVUIPBMPKJQ-UHFFFAOYSA-N 0.000 description 1
- XFGYUNVIMSXNNA-UHFFFAOYSA-N ethyl 4,5-diaminopyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC(N)=C(N)C=N1 XFGYUNVIMSXNNA-UHFFFAOYSA-N 0.000 description 1
- KNWHCOUOZIOQCV-UHFFFAOYSA-N ethyl 5-amino-6-nitropyridine-3-carboxylate Chemical compound NC=1C=C(C=NC1[N+](=O)[O-])C(=O)OCC KNWHCOUOZIOQCV-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical group C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical group [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- POFDSYGXHVPQNX-UHFFFAOYSA-N triazolo[1,5-a]pyrimidine Chemical compound C1=CC=NC2=CN=NN21 POFDSYGXHVPQNX-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| PL40825114 | 2014-05-19 | ||
| PCT/IB2015/053549 WO2015177688A1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2688084T3 true ES2688084T3 (es) | 2018-10-30 |
Family
ID=53434395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15730261.3T Active ES2688084T3 (es) | 2014-05-19 | 2015-05-14 | Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10138245B2 (enExample) |
| EP (1) | EP3145930B1 (enExample) |
| JP (1) | JP6455947B2 (enExample) |
| KR (1) | KR102404650B1 (enExample) |
| CN (1) | CN106459060B (enExample) |
| AU (1) | AU2015263013B2 (enExample) |
| CA (1) | CA2946258C (enExample) |
| DK (1) | DK3145930T3 (enExample) |
| EA (1) | EA030330B9 (enExample) |
| ES (1) | ES2688084T3 (enExample) |
| HR (1) | HRP20181027T1 (enExample) |
| HU (1) | HUE039847T2 (enExample) |
| MX (1) | MX367647B (enExample) |
| PL (2) | PL408251A1 (enExample) |
| PT (1) | PT3145930T (enExample) |
| SI (1) | SI3145930T1 (enExample) |
| WO (1) | WO2015177688A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017007301A1 (en) * | 2015-07-06 | 2017-01-12 | Universiti Sains Malaysia | Compound and method for inhibiting sirtuin activities |
| KR102587382B1 (ko) * | 2016-04-29 | 2023-10-12 | 솔루스첨단소재 주식회사 | 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
| CN111410657B (zh) * | 2019-01-08 | 2024-05-21 | 北京鼎材科技有限公司 | 一种发光材料及其应用 |
| WO2025160629A1 (en) * | 2024-01-31 | 2025-08-07 | Certa Therapeutics Pty Ltd | Proton sensing gpcr modulators |
| US20250276984A1 (en) * | 2024-02-20 | 2025-09-04 | Iambic Therapeutics, Inc. | Solid state forms of her2 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
-
2014
- 2014-05-19 PL PL408251A patent/PL408251A1/pl unknown
-
2015
- 2015-05-14 EP EP15730261.3A patent/EP3145930B1/en active Active
- 2015-05-14 PT PT15730261T patent/PT3145930T/pt unknown
- 2015-05-14 CA CA2946258A patent/CA2946258C/en active Active
- 2015-05-14 ES ES15730261.3T patent/ES2688084T3/es active Active
- 2015-05-14 AU AU2015263013A patent/AU2015263013B2/en active Active
- 2015-05-14 EA EA201692264A patent/EA030330B9/ru not_active IP Right Cessation
- 2015-05-14 KR KR1020167035389A patent/KR102404650B1/ko active Active
- 2015-05-14 DK DK15730261.3T patent/DK3145930T3/en active
- 2015-05-14 CN CN201580025963.XA patent/CN106459060B/zh active Active
- 2015-05-14 US US15/311,698 patent/US10138245B2/en active Active
- 2015-05-14 HR HRP20181027TT patent/HRP20181027T1/hr unknown
- 2015-05-14 MX MX2016015180A patent/MX367647B/es active IP Right Grant
- 2015-05-14 JP JP2016568435A patent/JP6455947B2/ja active Active
- 2015-05-14 HU HUE15730261A patent/HUE039847T2/hu unknown
- 2015-05-14 SI SI201530382T patent/SI3145930T1/sl unknown
- 2015-05-14 WO PCT/IB2015/053549 patent/WO2015177688A1/en not_active Ceased
- 2015-05-14 PL PL15730261T patent/PL3145930T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2946258C (en) | 2023-06-06 |
| MX367647B (es) | 2019-08-29 |
| EA030330B1 (ru) | 2018-07-31 |
| EP3145930B1 (en) | 2018-07-04 |
| JP2017521364A (ja) | 2017-08-03 |
| US10138245B2 (en) | 2018-11-27 |
| CA2946258A1 (en) | 2015-11-26 |
| PL3145930T3 (pl) | 2018-11-30 |
| US20170114064A1 (en) | 2017-04-27 |
| KR20170005860A (ko) | 2017-01-16 |
| DK3145930T3 (en) | 2018-09-24 |
| CN106459060A (zh) | 2017-02-22 |
| KR102404650B1 (ko) | 2022-06-02 |
| JP6455947B2 (ja) | 2019-01-23 |
| HUE039847T2 (hu) | 2019-02-28 |
| MX2016015180A (es) | 2017-03-23 |
| WO2015177688A1 (en) | 2015-11-26 |
| PL408251A1 (pl) | 2015-11-23 |
| AU2015263013B2 (en) | 2018-10-04 |
| PT3145930T (pt) | 2018-10-11 |
| EA030330B9 (ru) | 2018-09-28 |
| HRP20181027T1 (hr) | 2018-08-24 |
| AU2015263013A1 (en) | 2016-11-17 |
| CN106459060B (zh) | 2019-04-05 |
| EA201692264A1 (ru) | 2017-04-28 |
| EP3145930A1 (en) | 2017-03-29 |
| SI3145930T1 (sl) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2688084T3 (es) | Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A | |
| CA2865957C (en) | Compounds for treating spinal muscular atrophy | |
| CA2868026C (en) | Compounds for treating spinal muscular atrophy | |
| US9399649B2 (en) | Compounds for treating spinal muscular atrophy | |
| CA2863874C (en) | Compounds for treating spinal muscular atrophy | |
| CN109721620A (zh) | Hpk1抑制剂及其用途 | |
| ES2770693T3 (es) | Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon | |
| JP2018519273A (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| CA3219925A1 (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer | |
| CN118084916A (zh) | 三并杂环类化合物及其用途 | |
| US20240368188A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| BR112016027023B1 (pt) | Derivados de triazol fundidos como inibidores de fosfodiesterase 10a | |
| WO2024220633A1 (en) | Pyrrolopyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| KR20250174938A (ko) | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 티아졸로피리딘 유도체 | |
| KR20250172585A (ko) | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서 피롤로피리딘 유도체 | |
| KR20250172652A (ko) | 신경학적 및 정신의학적 장애의 치료에 유용한 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 1,6-나프티리딘 유도체 | |
| CN120936610A (zh) | 可用于治疗神经障碍和精神障碍的作为毒蕈碱型乙酰胆碱受体m4正向别构调节剂的1,6-萘啶衍生物 | |
| JPWO2000034277A1 (ja) | スルホンアミド化合物およびその医薬用途 | |
| NZ626279B2 (en) | Quinoline derivatives as pde10a enzyme inhibitors |